Arvinas (NASDAQ:ARVN) Posts Quarterly Earnings Results, Beats Expectations By $2.95 EPS

Arvinas (NASDAQ:ARVN) released its earnings results on Tuesday. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $2.95, FiscalAI reports. The company had revenue of $249.70 million during the quarter, compared to the consensus estimate of $60.71 million. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The firm’s quarterly revenue was up 1014.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.84) earnings per share.

Here are the key takeaways from Arvinas’ conference call:

• VEPPANU was approved by the FDA as the first PROTAC degrader and licensed to Rigel, which is expected to make the drug available soon. The deal and approval generated substantial Q2 revenue, including a $50 million Pfizer milestone and $62.5 million in license revenue.
• Arvinas expects multiple clinical catalysts, including initial ARV-393 BCL-6 degrader data by year-end 2026, ARV-027 muscle-exposure and degradation data in the first half of 2027, and additional ARV-102 biomarker data in October.
• ARV-393 enrollment accelerated near predicted efficacious dose levels, but most 2026 data will come from earlier, likely subtherapeutic cohorts and include an unusually high proportion of T-cell lymphoma patients. More mature monotherapy and glofitamab-combination data, including DLBCL patients, are planned for 2027.
• Regulatory requests have pushed the start of ARV-102 trials in PSP from 2026 into 2027, delaying the program’s planned phase I-B and registrational-oriented studies.
• The company reported $567.9 million in cash, cash equivalents, and marketable securities and reiterated that its cash runway extends into the second half of 2028, supporting continued investment in its early-stage oncology and neurology pipeline.

Arvinas Stock Up 13.8%

Arvinas stock traded up $1.11 during midday trading on Tuesday, hitting $9.17. 469,543 shares of the stock were exchanged, compared to its average volume of 815,419. Arvinas has a 52 week low of $6.05 and a 52 week high of $14.51. The stock has a market capitalization of $591.58 million, a PE ratio of -2.79 and a beta of 1.71. The company has a fifty day simple moving average of $8.07 and a two-hundred day simple moving average of $10.32.

Insider Activity

In other Arvinas news, insider Noah Berkowitz sold 11,108 shares of Arvinas stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total transaction of $110,413.52. Following the transaction, the insider directly owned 191,395 shares in the company, valued at approximately $1,902,466.30. The trade was a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Andrew Saik sold 11,139 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,721.66. Following the completion of the transaction, the chief financial officer directly owned 193,128 shares of the company’s stock, valued at approximately $1,919,692.32. The trade was a 5.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 41,728 shares of company stock valued at $402,649 in the last quarter. Company insiders own 7.30% of the company’s stock.

Institutional Trading of Arvinas

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new stake in shares of Arvinas during the first quarter worth $727,000. Jacobs Levy Equity Management Inc. acquired a new position in Arvinas in the 1st quarter worth $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock worth $271,000 after purchasing an additional 2,122 shares during the period. Millennium Management LLC increased its holdings in Arvinas by 208.4% during the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after purchasing an additional 885,483 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Arvinas by 108.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company’s stock valued at $6,339,000 after purchasing an additional 469,394 shares during the period. 95.19% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ARVN has been the subject of several recent research reports. Zacks Research raised Arvinas from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 26th. Citigroup lifted their price target on shares of Arvinas from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. BTIG Research boosted their price target on shares of Arvinas from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Barclays raised their price objective on shares of Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Arvinas from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 26th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.42.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.